Status:
UNKNOWN
Quality Of Life and Drug Use in Patients With CAR-T Cells
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Patients With Diffuse Large B-cell Lymphoma Treated With CART-cells
Eligibility:
All Genders
18+ years
Brief Summary
CAR-T cells are a major therapeutic innovation in the management of patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) in 3rd line or more. Kymriah® and Yescarta® are the first...
Eligibility Criteria
Inclusion
- Over 18 years old
- Eligible for treatment with CAR-T cells (outside any clinical trial) in an indication of DLBCL and for which treatment is scheduled
- Follow-up in the Hematology department of the Hospices Civils de Lyon
- Without major psychiatric disorder likely to interfere with the conduct of the study, in the opinion of the investigator
- Having given his non-opposition to participate in the study.
Exclusion
- In an institution
- Under legal protection
Key Trial Info
Start Date :
March 31 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2023
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04914091
Start Date
March 31 2021
End Date
April 30 2023
Last Update
February 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospices Civils de Lyon -Groupement Hospitalier Sud Service pharmaceutique, Unité de Pharmacie Clinique Oncologique
Pierre-Bénite, France, 69495